Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus

Abstracts

OBJETIVO: avaliar os fatores epidemiológicos e genéticos associados à gravidade da Bronquiolite Viral Aguda (BVA) pelo Vírus Sincicial Respiratório (VSR). FONTE DOS DADOS: foram utilizados descritores "bronchiolitis", "risk factor", "genetics" e "respiratory syncytial virus" e todas as combinações entre eles, nas bases de dados PubMed, SciELO e Lilacs publicados após o ano de 2000 e que incluíram indivíduos menores de dois anos de idade. SÍNTESE DOS DADOS: foram encontrados 1.259 artigos e lidos seus respectivos resumos. Destes foram selecionados 81 que avaliaram fatores de risco para a gravidade da BVA para leitura na íntegra, e foram incluídos os 60 estudos mais relevantes. Os fatores epidemiológicos associados com a gravidade da BVA pelo VSR foram: prematuridade, tabagismo passivo, baixa idade, ausência de aleitamento materno, doença pulmonar crônica, cardiopatia congênita, sexo masculino, etnia, coinfecção viral, baixo peso na admissão hospitalar, tabagismo materno na gestação, dermatite atópica, ventilação mecânica no período neonatal, antecedente materno de atopia e/ou asma na gestação, estação do nascimento, baixo nível socioeconômico, síndrome de Down, poluição ambiental, morar em altitude acima de 2.500 metros do nível do mar e parto cesariana. Em contrapartida, algumas crianças com BVA grave não apresentam nenhum desses fatores de risco. Neste sentido, estudos recentes têm verificado a influência de fatores genéticos relacionados à gravidade da BVA pelo VSR. Polimorfismos dos genes TLRs, RANTES, JUN, IFNA5, NOS2, CX3CR1, ILs e VDR têm-se mostrado associados com a evolução mais grave da BVA pelo VSR. CONCLUSÃO: a gravidade da BVA pelo VSR é um fenômeno dependente da interação entre variáveis epidemiológicas, ambientais e genéticas em seus diferentes graus de interação.

Bronquiolite; Fatores de risco; Vírus sincicial respiratório; Genética

REVIEW ARTICLE

^IPediatrics Department, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil

^IIMedical Genetics Department, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil

^IIIBiology Institute, Universidade Estadual de Campinas, Campinas, SP, Brazil

ABSTRACT

OBJECTIVE: to assess the epidemiological and genetic factors associated with severity of acute viral bronchiolitis (AVB) by respiratory syncytial virus (RSV).

DATA SOURCE: the key words ''bronchiolitis'', ''risk factor'', ''genetics'' and ''respiratory syncytial virus'', and all combinations among them were used to perform a search in the PubMed, SciELO, and Lilacs databases, of articles published after the year 2000 that included individuals younger than 2 years of age.

DATA SYNTHESIS: a total of 1,259 articles were found, and their respective summaries were read. Of these, 81 were selected, which assessed risk factors for the severity of AVB, and were read in full; the 60 most relevant studies were included. The epidemiologic factors associated with AVB severity by RSV were prematurity, passive smoking, young age, lack of breastfeeding, chronic lung disease, congenital heart disease, male gender, ethnicity, viral coinfection, low weight at admission, maternal smoking during pregnancy, atopic dermatitis, mechanical ventilation in the neonatal period, maternal history of atopy and/or asthma during pregnancy, season of birth, low socioeconomic status, Down syndrome, environmental pollution, living at an altitude > 2,500 meters above sea level, and cesarean section birth. Conversely, some children with severe AVB did not present any of these risk factors. In this regard, recent studies have verified the influence of genetic factors on the severity of AVB by RSV. Polymorphisms of the TLRs, RANTES, JUN, IFNA5, NOS2, CX3CR1, ILs, and VDR genes have been shown to be associated with more severe evolution of AVB by RSV.

CONCLUSION: the severity of AVB by RSV is a phenomenon that depends on the varying degrees of interaction among epidemiological, environmental, and genetic variables.

Keywords: Bronchiolitis; Risk factors; Respiratory syncytial virus; Genetics

Introduction

Acute viral bronchiolitis (AVB) caused by respiratory syncytial virus (RSV) is the primary infection of the lower airways in children under 2 years of age worldwide, and it is the main cause of hospitalization in this age group in developed countries.¹ Although all children are infected with RSV by the age of three, most infections are mild and have no sequelae. The mechanisms involved with the severity of AVB caused by RSV are not yet fully understood. Why does RSV infection present such variable evolution in different patients? Why does one child with RSV remain asymptomatic and another child dies? When assessing the severity of AVB caused by RSV, which factors are more often associated: genetic and/or epidemiological/environmental factors? These questions have intrigued researchers and remain without definitive answers.

There are 3,000 to 4,000 deaths annually in the United States due to AVB caused by RSV.² The prevalence of hospitalization due to RSV in the United States is 48.9 per 1,000 in children younger than 3 months, 26 per 1,000 in those younger than 1 year, and 1.8 per 1,000 in children aged 1 to 5 years, with 132,000 to 172,000 hospitalizations/year due to RSV in children under 5 years.³ In the United States, there are, on average, 22.8 visits to the emergency room caused by RSV per 1,000 infants; 29% of whom are hospitalized. That represents an annual spending of 50.5 million dollars on emergency room visits and 650 million dollars on hospitalizations.⁴ In other regions, the rate of hospitalization per 1,000 infants with RSV varies from 8.7 in Australia⁵ to 60 in Japan.⁶ In Australia, the incidence of RSV is from

110.0 to 226.5 per 1,000 infants, and the annual cost is estimated at $ 50 million dollars, which is more significant than the costs of Influenza and Rotavirus infections.⁵ In Europe, RSV is responsible for 45% of hospitalizations for lower respiratory infection in children younger than 2 years.⁶

In Brazil, a study of 5,304 children younger than 1 year showed that 113 (2.1%) were hospitalized due to AVB.⁷ Among the children hospitalized for RSV, 2.7% were admitted to the intensive care unit (ICU), 1.5% required assisted ventilation, and 0.2% died.⁸

Infection by RSV has variable severity with clinical manifestations from mild symptoms in the upper respiratory tract to bronchiolitis and pneumonia, and may develop into the severe form, requiring ICU admission and mechanical ventilation, and at times leading to death. To date, the treatment of AVB by RSV is supportive. It has been demonstrated that, in the United States, of 1.1 million children younger than two years hospitalized for RSV in a period of eight years, the highest percentage of hospitalizations occurred between 3 and 6 months of age, thus affecting a population range at risk of mortality.⁹ The first infections are usually symptomatic and often affect the lower airways; subsequent infections are usually milder.

RSV is the agent responsible for AVB in 41.7%¹⁰ to 83.6% of cases.¹¹ In Brazil, RSV was responsible for 31.9%¹² to 64% of hospitalized patients with AVB.¹³ Although other viruses are detected in patients with AVB, such as adenovirus, bocavirus, Influenza A, Influenza B, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, rhinovirus, and metapneumovirus,^10,11 the establishment of codetection or coinfection has been a critical aspect yet to be considered.¹⁴ The second most common virus in AVB is the rhinovirus, corresponding to approximately 18% of cases.¹⁵ In Brazil, it was found that viral coinfection occurs in 40% of AVB cases and that the most common virus after RSV is the rhinovirus, occurring in 40% of cases.¹⁶

Epidemiological factors associated with the severity of AVB by RSV are known and have been reported in the literature; however, some children with severe AVB do not have any of these risk factors (Table 1). In this regard, recent studies have assessed the influence of genetic factors related to disease severity (Table 2).

Due to the possibility of AVB evolving into a more severe form, it becomes important to identify genetic and environmental risk factors that can contribute to its greater severity.

Recently, several studies have led to the creation of guidelines around the world, showing that children at high risk of acquiring severe RSV infection should receive passive immunization with monoclonal antibody against RSV (palivizumab), which promotes protection against severe forms of the disease. After the introduction of palivizumab, a 48% reduction in hospitalizations of infants with chronic lung disease of prematurity was observed.¹⁷ A vaccine aimed at preventing AVB by RSV has yet to be developed, despite efforts in this regard since the 1960s.¹

The objective of this review was to evaluate the epidemiological and genetic factors that contribute to the severity of AVB by RSV, allowing for better patient management and prediction of risk groups associated with the disease, decreasing costs for the health system, and allowing for a reduction in the number of hospitalizations and deaths.

Methods

The key words ''bronchiolitis'', ''risk factor'', ''genetics'', and ''respiratory syncytial virus'' and all their combinations were used in a search conducted at the PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Sci-ELO (http://www.scielo.org/php/index.php), and LILACS (http://lilacs.bvsalud.org/en/) databases of articles published after the year 2000 that included individuals younger than 2 years old. The last search was performed in October of 2012.

A total of 1,259 articles were found, of which all abstracts were read. Of these, 81 that assessed risk factors for AVB severity were selected to be read in full, and the 60 most relevant studies were included in the analysis (Fig. 1).

Results and discussion

Risk factors

The association of genetic and epidemiological/environmental factors as precursors for severe AVB by RSV has been reported in the literature. Certain risk factors are better known and are associated with disease severity, including prematurity,¹⁸ passive smoking,¹⁹ younger age,¹⁶ absence of breastfeeding,²⁰ chronic lung disease, and congenital heart disease.²¹ However, other factors, such as genetic factors and other epidemiological data, show no evident confirmatory associations, and require further studies as markers of severity in AVB caused by RSV (Fig. 2).

Prematurity

Prematurity, without the presence of bronchopulmonary dysplasia, has a seven-fold higher risk factor of AVB by RSV.¹⁸ A Brazilian study demonstrated that in 77 patients with AVB prematurity was associated with a higher probability of ICU admission, with an OR of 24.51 (95% CI: 3.21 to 186.92).¹⁶ In 230 infants age < 24 months, prematurity (gestational age < 37 weeks) was a risk factor for hospitalization.²² Among 284 patients admitted to the ICU for AVB, 30% were preterm.²³ Another Brazilian cohort study of 5,301 children followed for a year showed that 113 were hospitalized for AVB, and the risk of hospitalization was 80% higher in children whose mothers had pregnancies lasting less than 37 weeks.⁷ Prematurity in patients with AVB by RSV was also associated with increased risk of hypoxemia and respiratory failure requiring mechanical ventilation.²⁴ In a retrospective analysis of 4,800 infants hospitalized for AVB, it was concluded that prematurity and positive RSV represented risk factors for disease severity.²⁵

Passive smoking

In the assessment of 378 hospitalized patients with AVB, passive smoking was a risk factor for need for supplemental oxygen and mechanical ventilation,¹⁹ and in another sample of 240 children hospitalized for AVB, it was observed that passive smoking was associated with greater clinical severity and longer hospitalization.²⁶ In a meta-analysis that included 60 studies, passive smoking was a significant risk factor for AVB.²⁷ In a prospective analysis of 206 patients hospitalized for AVB by RSV, children exposed to postnatal maternal smoking had lower levels of hemoglobin oxygen saturation than those not exposed (89.8% versus 92.2%, p = 0.01).²⁸ In Brazil, it was demonstrated that the risk of hospitalization for AVB was 57% higher in children exposed to maternal smoking than those not exposed.⁷

Young age

It has been well established in the literature that the younger the child, the greater the clinical severity of AVB by RSV. In a Brazilian study, age had an OR of 0.838 (95% CI: 0.718-0.979) compared to hospitalization, indicating that older age was associated with a lower incidence of hospitalization.¹⁶ Patients younger than 2 months had a longer length of hospital stay (6 versus 5 days, p < 0.00001) and increased risk of icu admission (or 3.4; 95% ci: 2.5 to 4.6).²⁹ In the evaluation of 229 patients admitted to the ICU for AVB, age was found to be inversely proportional to the time spent in the ICU and time in ventilatory support;³⁰ the same was observed in a prospective study of 1,456 patients with AVB, which compared hospitalization in the ICU and in the hospital ward and showed that age younger than 2 months was as a risk factor for ICU admission (26% versus 53%; OR = 4.1; 95% CI: 2.1 to 8.3).³¹ In the evaluation of 310 patients younger than 12 months with AVB, it was concluded that younger age was the main factor associated with the severity of clinical manifestations,³² which was also observed in the evaluation of 284 patients admitted to the ICU for AVB, where age less than 6 weeks was the main risk factor, accounting for 45% of the patients.²³ The younger the child, the lower the levels of hemoglobin oxygen saturation in 206 patients hospitalized for AVB by RSV; it was shown that for each month younger the child was, there was a reduction in 0.41% in oxygen saturation.²⁸ The relationship of age and presence of hospitalization for respiratory infection could be observed in the evaluation of 347 patients with acute respiratory infection, 234 inpatients and 112 outpatients, where the age of hospitalized patients was younger (8 versus 19 months, p < 0.001).³³

Maternal breastfeeding

Breastfeeding is protective factor against severe AVB. A study of 12,474 children with bronchiolitis, of whom 1,588 required hospitalization, demonstrated that breastfeeding not starting in the maternity ward lead to a higher risk factor for hospitalization for AVB.²⁰ A Brazilian study with 175 children hospitalized for AVB demonstrated that duration of exclusive breastfeeding was inversely related to the duration of oxygen use and of hospitalization, indicating that for every month of exclusive breastfeeding there was a decrease of 11 hours in the time of oxygen use.³⁴ Children weaned before one month of life had a 7.7-fold greater risk of being hospitalized for AVB.⁷ The importance of breastfeeding was further demonstrated in a study with 240 children hospitalized for AVB that concluded that breastfeeding an infant for less than four months was a risk factor for severe outcome and longer hospitalization time.²⁶

Chronic pulmonary disease

The presence of chronic pulmonary disease, mainly bronchopulmonary dysplasia, is related to the greater severity of AVB.^21,35 Infants with bronchopulmonary dysplasia have a 6.7-fold risk of death from AVB when compared to infants without this condition.³⁶

Congenital heart disease

The presence of congenital heart disease is associated with increased severity of AVB.²¹ A recent study found that the length of hospitalization was higher in children who had congenital heart disease (6 versus 5 days; p < 0.0001),²⁹ and a retrospective study of 764 hospitalized patients with AVB showed that the presence of congenital heart disease was associated with a 50% longer length of hospital stay than in children without heart disease.³⁷

Gender

Male patients with AVB have a higher risk of requiring supplemental oxygen and mechanical ventilation when compared to female patients.¹⁹ A study of 12,474 infants with AVB, of whom 1,588 were hospitalized, demonstrated that the risk of hospitalization was higher in male patients.²⁰

Ethnicity

The role of ethnicity as a risk factor remains unclear, with controversial results in the literature. One study reported that patients of African descent have better progress when compared to Caucasians,²⁸ while another study indicated the opposite.⁴ In some isolated populations, a few observations have been made: in New Zealand, patients of Maori origin had worse outcome;²² the same was observed for Native Americans and those originating in Alaska, who had more severe disease when compared to Caucasian patients.³⁸

Etiology and presence of viral coinfection

There are controversial results in the literature regarding the influence of the type of virus causing the disease on a more severe evolution.¹⁴ Some studies suggest that RSV is a factor of severity for AVB when compared to other viruses.^11,32 A recent study demonstrated that severe AVB by RSV leads to prolonged hospital stay (6 versus 5 days, p < 0.0001), higher risk of icu admission (or 2.7; 95% CI: 1.87 to 3.9), and increased need for oxygen therapy (OR 2.2; 95% CI: 1.8-2.6).²⁹ A Brazilian study showed that pulse oximetry < 90% at hospital admission for lower respiratory tract infection was associated with rsv infection.³⁹ However, other studies have shown that RSV does not lead to greater clinical severity when compared to other viruses, as in a Brazilian study of 89 hospitalized patients, which did not show any difference in severity between patients who had RSV and those who did not;⁴⁰ and another study showed that positive RSV had no influence on the time of hospitalization.⁴¹ Regarding presence of viral coinfection, one study demonstrated that viral coinfection is responsible for increased severity of AVB.²¹ Other studies suggest that viral coinfection does not increase the severity of AVB,⁴² including a study in Brazil, which evaluated 176 patients and concluded that the clinical severity of AVB by RSV did not increase due to the presence of viral coinfection.⁴³

Currently, through the development of quantitative PCR, the importance of the viral load on AVB severity has been studied, as well as the differentiation of coinfection and viral codetection, aspects that were little known and often disregarded in the literature.⁴⁴

Other risk factors associated with AVB severity

(i) low weight at admission;¹⁹ (ii) maternal smoking during pregnancy;^20,45 (iii) atopic dermatitis;³⁵ (iv) mechanical ventilation in the neonatal period;²¹ (v) maternal history of atopy;¹⁵ (vi) history of maternal asthma during pregnancy;⁴⁵ (vii) season of birth;²² (viii) low socioeconomic status;^7,20 (ix) Down syndrome;^37,46 (x) environmental pollution;⁴⁷ (xi) living at an altitude higher than 2,500 meters above sea level;⁴⁸ and (xii) C-section delivery.⁴⁹

Genetic factors

Despite the knowledge of the aforementioned risk factors, most infants hospitalized for AVB present no such factors. This led the researchers to believe that the epidemiological factors were not solely responsible for determining the clinical severity of AVB by RSV. Thus, genetic characteristics have been studied as an active risk factor in AVB severity. It has been estimated that there are over 10 million variations in the human genome (polymorphisms), and these may be associated with the clinical variability in diseases such as AVB, which have recently been the object of population studies. In this context, some studies addressing gene variations associated with immune response were performed in severe AVB by RSV.

A recent study evaluated 12,346 twins born in Denmark over a period of 10 years, and found an agreement between them regarding hospitalization for RSV. The agreement was 0.66 in homozygous twins and 0.53 in dizygotic ones, estimating a genetic contribution of 16% to 20% for disease severity,⁵⁰ which contributes to the hypothesis of a genetic factor influencing AVB severity.

In AVB, infection is restricted to the surface cells of the respiratory epithelium, especially the hair cells of the bronchioles and type 1 pneumocytes in alveoli, and is opposed by the innate and adaptive immune response. RSV is recognized by epithelial cells through receptors specialized in recognition of pathogen-associated molecular patterns, known as pattern recognition receptors (PRRs) in the form of trans-membrane molecules termed toll-like receptors (TLRs), present in macrophages and dendritic cells, which occur in the production of proinflammatory cytokines (Interleukin 6, 8, 10, and 13, tumor necrosis factor, RANTES, CX3CK1) and surfactant proteins.

Some of the factors have direct antiviral properties, while others stimulate the activation of natural killer cells, granulocytes, monocytes, and macrophages, initiating the adaptive immune response.

The main TLR responsible for the recognition of RSV is TLR4. TLR4 polymorphisms were associated with risk of severe AVB by RSV, but the results have been controversial. A better understanding of this question is important to more effectively identify those infants at risk for more severe AVB evolution. The presence of TLR4, Asp299Gly (rs4986790), and Thr399Ile (rs4986791) polymorphisms was verified in 99 infants hospitalized for severe AVB by RSV, 82 outpatients treated for this disease, and 90 healthy adults. TLR4 polymorphisms were more frequent in the group with severe AVB compared to the other two groups, leading the authors to conclude that the presence of TLR4 polymorphisms was associated with higher disease severity.⁵¹ Another study evaluated the influence of Asp299Gly and Thr399Ile polymorphisms in TLR4 gene on cytokine production and demonstrated that there was no influence, concluding that the determination of TLR4 gene polymorphisms does not have any benefit in clinical practice.⁵² Another study with 312 patients and 356 controls evaluated the influence of Asp299Gly polymorphism in TLR4 gene regarding the susceptibility to severe AVB by RSV and demonstrated that this polymorphism does not influence disease severity. The authors concluded that the severity of AVB by RSV appears to be associated with constitutional and environmental factors.⁵³

One study analyzed 52 children with AVB by RSV (26 outpatients, 21 hospitalized in the hospital ward, and five admitted to the ICU), and found that the presence of Asp299Gly and Thr399Ile polymorphisms in the TLR4 gene, and a dysfunction of peripheral blood mononuclear cells stimulated by phytohemagglutinins expressed by hyper-responsiveness in response to lipopolysaccharides, were associated with increased severity of AVB by RSV.⁵⁴

At the evaluation of D259G and T359I polymorphisms of TLR4 in 131 infants with severe AVB by RSV compared with 270 controls, polymorphisms alone were not associated with disease severity, but the presence of a gene haplotype with both polymorphisms showed a significant association with severity (p < 0.001).⁵⁵

One study investigated whether polymorphisms in other TLRs, in addition to TLR4, could be related to susceptibility to AVB by RSV. Thus, 19 polymorphisms in TLRs 1, 2, 3, 5, 6, 9, and 10 were evaluated; an association was found between polymorphisms in receptors 9 and 10.⁵⁶

In the evaluation of 106 children hospitalized for AVB by RSV and 120 controls (healthy adults with no history of severe respiratory infection) to verify the association of three polymorphisms (-28C/G, -403G/A, and In1.1T/C) in the RANTES gene with disease severity, there was no association between disease severity and polymorphisms in isolation, but the combination of the three polymorphisms, forming a gene haplotype, was more common in cases than in controls, leading the authors to conclude that there was an association between polymorphisms in the RANTES gene and severity of AVB by RSV.⁵⁷

One study found that Thr1Meth polymorphism (rs10735810) in the vitamin D receptor was associated with AVB, with the T ''minor'' allele showing a greater propensity to AVB.⁵⁸

Another study analyzed 384 single nucleotide polymorphisms in 470 children hospitalized for AVB by RSV and 1,008 controls, and found that polymorphisms in the vitamin D receptor (rs10735810), JUN (rs11688), IFNA5 (rs10757212), and NOS-2 (rs1060826) genes showed association with AVB. The authors concluded that polymorphisms in innate immune response genes are important in determining susceptibility to the AVB.⁵⁹

Researchers evaluated whether the presence of polymorphisms in the CX3CR1 receptor present in leukocytes, which binds to G protein of RSV, could have a correlation with AVB severity. They evaluated 82 children hospitalized for AVB by RSV, comparing them with 120 adults with no history of severe respiratory infection, and concluded that the T280 M polymorphism was more frequent in cases than in controls (37.8% vs. 20.8%; OR: 2.03; 95% CI: 1.1 to 3.9) demonstrating an association between the polymorphism and severity of infection.⁶⁰

Pulmonary surfactant proteins SP-A, B, C, and D, in addition to maintaining the alveolar surface tension, also participate in immune mechanisms regulating the release of proinflammatory cytokines and participate in chemotaxis and tissue repair. A recent study investigated whether polymorphisms in SP-A1, SP-A2, and SP-D genes were associated with the severity of RSV infection. A prospective study with 118 children younger than 6 months with RSV infection and 104 controls with no history of severe respiratory infection was conducted, and significant differences were found for some polymorphisms. When analyzed for the presence of gene haplotypes, there was a significant association between their occurrence and severity of RSV infection evolution (p < 0.001).⁶¹

Interleukins (IL) have an important role in immune response, and associations between different polymorphisms and genic haplotypes of IL-4, IL-8, IL-10, IL-13, and IL-18 genes with increased severity of RSV infection have been found. The studies are controversial; the association usually has low OR and some studies have shown no association. In one study, the association was only significant in patients older than 6 months for IL-4 or younger than 6 months for IL-10, suggesting an age-dependent effect on Th1/Th2 balance.⁶²

As polymorphisms in genes related to the presence and increased severity of AVB are associated with immune response, their identification will allow for a better understanding of which pathways are involved in the immune response to the virus and thus collaborate with a more complete understanding of the disease. Knowledge of polymorphisms associated more severe evolution illuminates the possibility of introducing new therapies conditioned by pharmacogenetics.

Conclusion

Severe AVB is the most frequent complication of RSV infection, accounting for a large number of hospitalizations and high costs, and can lead to death.

Advances have occurred in recent years regarding the understanding of of the severity variability of AVB by RSV. The main epidemiological factors include prematurity, passive smoking, young age, lack of breastfeeding, chronic lung disease, and congenital heart disease. Other factors, such as gender and ethnicity, virus type, and presence of viral coinfection, remain controversial.

There are reports of other factors that can also influence severity, but these require further studies. They include low weight at admission, maternal smoking during pregnancy, atopic dermatitis, mechanical ventilation in the neonatal period, maternal history of atopy, maternal history of asthma during pregnancy, birth season, low socioeconomic status, Down syndrome, environmental pollution, living at an altitude higher than 2,500 meters above sea level, and cesarian section delivery. Regarding genetic factors, some polymorphisms appear to be associated with more severe evolution; the most often studied gene polymorphisms are TLR4, TLR9, TLR10, RANTES, VDR, JUN, IFNA5, NOS-2, and CX3CR1, as well as genes encoding surfactant proteins and IL-4, IL-8, IL-10, IL-13, and IL-18.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors would like to thank the research group in chronic obstructive pulmonary diseases of Faculdade de Ciências Médicas da Unicamp, the pulmonary function lab of Centro de Investigação em Pediatria, and the multiuser laboratory of the Department of Medical Genetics http://laboratoriomultiusuario.com.br.

References

• 1. Chávez-Bueno S, Mejías A, Welliver RC. Respiratory syncytial virus bronchiolitis: current and future strategies for treatment and prophylaxis. Treat Respir Med. 2006;5:483-94.
• 2. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev. 2004;5:S119-26.
• 3. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5-9.
• 4. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143:S127-32.
• 5. Ranmuthugala G, Brown L, Lidbury BA. Respiratory syncytial virus - the unrecognised cause of health and economic burden among young children in Australia. Commun Dis Intell. 2011;35:177-84.
• 6. Simões EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J. 2003;22:S13-8; discussion S18-20.
• 7. Albernaz EP, Menezes AM, César JA, Victora CG, Barros FC, Halpern R. Risk factors associated with hospitalization for bronchiolitis in the post-neonatal period. Rev Saude Publica. 2003;37:485-93.
• 8. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065-9
• 9. Fryzek JP, Martone WJ, Groothuis JR. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Adv Ther. 2011;28:195-201.
• 10. Sung CC, Chi H, Chiu NC, Huang DT, Weng LC, Wang NY, et al. Viral etiology of acute lower respiratory tract infections in hospitalized young children in Northern Taiwan. J Microbiol Immunol Infect. 2011;44:184-90.
• 11. García ML, Ordobás Gabin M, Calvo Reya C, González Alvarez M, Aguilar Ruiz J, Arregui Sierra A, et al. Viral infection of the lower respiratory tract in hospitalized infants: etiology, clinical features and risk factors. An Esp Pediatr. 2001;55:101-7.
• 12. Riccetto AG, Ribeiro JD, Silva MT, Almeida RS, Arns CW, Baracat EC. Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks. Braz J Infect Dis. 2006;10:357-61.
• 13. Salomão Junior JB, Gardinassi LG, Simas PV, Bittar CO, Souza FP, Rahal P, et al. Human respiratory syncytial virus in children hospitalized for acute lower respiratory infection. J Pediatr (Rio J). 2011;87:219-24.
• 14. Sly PD, Jones CM. Viral co-detection in infants hospitalized with respiratory disease: is it important to detect? J Pediatr (Rio J). 2011;87:277-80.
• 15. Miller EK, Williams JV, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, et al. Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness. J Allergy Clin Immunol. 2011;127:883-91.
• 16. Nascimento MS, Souza AV, Ferreira AV, Rodrigues JC, Abramovici S, Silva Filho LV. High rate of viral identification and coinfections in infants with acute bronchiolitis. Clinics (São Paulo). 2010;65:1133-7.
• 17. Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008. Clin Epidemiol. 2011;3:245-50.
• 18. Gouyon JB, Rozé JC, Guillermet-Fromentin C, Glorieux I, Adamon L, DI Maio M, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2012 15:1-11.
• 19. Semple MG, Taylor-Robinson DC, Lane S, Smyth RL. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS One. 2011;6:e22425.
• 20. Koehoorn M, Karr CJ, Demers PA, Lencar C, Tamburic L, Brauer M. Descriptive epidemiological features of bronchiolitis in a population-based cohort. Pediatrics. 2008;122:1196-203.
• 21. Ochoa Sangrador C, González de Dios J; Grupo de Revisión del Proyecto aBREVIADo (BRonquiolitis-Estudio de Variabilidad, Idoneidad y Adecuación). [Consensus conference on acute bronchiolitis (VI): prognosis of acute bronchiolitis. Review of scientific evidence]. An Pediatr (Barc). 2010;72:354.e1-34.
• 22. Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, Redshaw N, et al. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect. 2008;136: 1333-41.
• 23. López Guinea A, Casado Flores J, Martín Sobrino MA, Espínola Docio B, de la Calle Cabrera T, Serrano A, García Teresa MA. Severe bronchiolitis. Epidemiology and clinical course of 284 patients. An Pediatr (Barc). 2007;67:116-22.
• 24. Chan PW, Lok FY, Khatijah SB. Risk factors for hypoxemia and respiratory failure in respiratory syncytial virus bronchiolitis. Southeast Asian J Trop Med Public Health. 2002;33:806-10.
• 25. Garcia CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126: e1453-60.
• 26. Chatzimichael A, Tsalkidis A, Cassimos D, Gardikis S, Tripsianis G, Deftereos S, et al. The role of breastfeeding and passive smoking on the development of severe bronchiolitis in infants. Minerva Pediatr. 2007;59:199-206.
• 27. Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011;12:5.
• 28. Bradley JP, Bacharier LB, Bonfiglio J, Schechtman KB, Strunk R, Storch G, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics. 2005;115:e7-14.
• 29. Hervás D, Reina J, Yañez A, Del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis. 2012;31:1975-81.
• 30. Oñoro G, Pérez Suárez E, Iglesias Bouzas MI, Serrano A, Martínez De Azagra A, et al. Severe bronchiolitis. Changes in epidemiology and respiratory support. An Pediatr (Barc). 2011;74:371-6.
• 31. Damore D, Mansbach JM, Clark S, Ramundo M, Camargo CA Jr. Prospective multicenter bronchiolitis study: predicting intensive care unit admissions. Acad Emerg Med. 2008;15:887-94.
• 32. Papoff P, Moretti C, Cangiano G, Bonci E, Roggini M, Pierangeli A, et al. Incidence and predisposing factors for severe disease in previously healthy term infants experiencing their first episode of bronchiolitis. Acta Paediatr. 2011;100:e17-23.
• 33. Vidaurreta SM, Marcone DN, Ellis A, Ekstrom J, Cukier D, Videla C. Acute viral respiratory infection in children under 5 years: Epidemiological study in two centers in Buenos Aires, Argentina. Arch Argent Pediatr. 2011;109:296-304.
• 34. Dornelles CT, Piva JP, Marostica PJ. Nutritional status, breastfeeding, and evolution of Infants with acute viral bronchiolitis. J Health Popul Nutr. 2007;25:336-43.
• 35. Al-Shehri MA, Sadeq A, Quli K. Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission. West Afr J Med. 2005;24:299-304.
• 36. Che D, Nicolau J, Bergounioux J, Perez T, Bitar D. Bronchiolitis among infants under 1 year of age in France: Epidemiology and factors associated with mortality. Arch Pediatr. 2012;19:700-6.
• 37. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatr. 2004;4:25.
• 38. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003; 22:S40-5.
• 39. Riccetto AG, Silva LH, Spilki FR, Morcillo AM, Arns CW, Baracat EC. Genotypes and clinical data of respiratory syncytial virus and metapneumovirus in brazilian infants: a new perspective. Braz J Infect Dis. 2009;13:35-9.
• 40. D'Elia C, Siqueira MM, Portes SA, Sant'Anna CC. Respiratory syncytial virus associated lower respiratory tract infections in hospitalized infants. Rev Soc Bras Med Trop. 2005;38:7-10.
• 41. Weigl JA, Puppe W, Schmitt HJ. Variables explaining the duration of hospitalization in children under two years of age admitted with acute airway infections: does respiratory syncytial virus have a direct impact? Klin Padiatr. 2004;216:7-15.
• 42. Brand HK, de Groot R, Galama JM, Brouwer ML, Teuwen K, Hermans PW, et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol. 2012;47:393-400
• 43. De Paulis M, Gilio AE, Ferraro AA, Ferronato AE, do Sacramento PR, Botosso VF, et al,. Severity of viral coinfection in hospitalized infants with respiratory syncytial virus infection. J Pediatr (Rio J). 2011;87:307-13.
• 44. Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14:38-45.
• 45. Carroll KN, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Wu P, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. Pediatrics. 2007;119:1104-12.
• 46. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis a prospective birth-cohort study. Pediatrics. 2007;120:e1076-81.
• 47. Karr C, Lumley T, Schreuder A, Davis R, Larson T, Ritz B, et al. Effects of subchronic and chronic exposure to ambient air pollutants on infant bronchiolitis. Am J Epidemiol. 2007;165:553-60.
• 48. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics. 2006;117:349-56.
• 49. Moore HC, de Klerk N, Holt P, Richmond PC, Lehmann D. Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery. Arch Dis Child. 2012;97:410-4.
• 50. Thomsen SF, Stensballe LG, Skytthe A, Kyvic KO, Backer V, Bisgaard H. Increased concordance of severe respiratory syncytial virus infection in identical twins. Pediatrics. 2008; 121:493-6.
• 51. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis. 2004;189:2057-63.
• 52. Douville RN, Lissitsyn Y, Hirschfeld AF, Becker AB, Kozyrskyj AL, Liem J, et al. TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus. PLoS One. 2010;5:e12087.
• 53. Löfgren J, Marttila R, Renko M, Rämet M, Hallman M. Toll-like receptor 4 Asp299Gly polymorphism in respiratory syncytial virus epidemics. Pediatr Pulmonol. 2010;45:687-92.
• 54. Mandelberg A, Tal G, Naugolny L, Cesar K, Oron A, Houri S, et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis. Clin Exp Immunol. 2006;144:48-52.
• 55. Puthothu B, Forster J, Heinzmann A, Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers. 2006;22:303-8.
• 56. Mailaparambil B, Krueger M, Heinze J, Forster J, Heinzmann A. Polymorphisms of toll like receptors in the genetics of severe RSV associated diseases. Dis Markers. 2008;25:59-65.
• 57. Amanatidou V, Sourvinos G, Apostolakis S, Neonaki P, Tsilimigaki A, Krambovitis E, et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J. 2008;27:38-42.
• 58. Kresfelder TL, Janssen R, Bont L, Venter M. Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African children. J Med Virol. 2011;83:1834-40.
• 59. Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, Doornbos G, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis. 2007;196:826-34.
• 60. Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J. 2006;25:410-4.
• 61. Ampuero S, Luchsinger V, Tapia L, Palomino MA, Larrañaga CE. SP-A1, SP-A2 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in Chilean infants. Infect Genet Evol. 2011;11:1368-77.
• 62. Mulet JF, Rodríguez de Torres BO. Viral induced bronchiolitis and genetics. An Pediatr (Barc). 2010;73:159-61.

Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus

Alfonso Eduardo Alvarez^I; Fernando Augusto de Lima Marson^I,*; Carmen Sílvia Bertuzzo^II; Clarice Weis Arns^III; José Dirceu Ribeiro^I

Publication Dates

• Publication in this collection
  12 Dec 2013
• Date of issue
  Dec 2013

History

• Received
  22 Jan 2013
• Accepted
  06 Feb 2013